Check out our comprehensive educational activities here

A Focus on Prognostic Indicators for Treatment in Patients with AML

Are you unsure if your patient is fit or unfit for intensive chemotherapy? In this newsletter, Dr. Wang describes a number of patient- and treatment-related factors that can be taken into account.

For more information on treatment selection in AML, click here.

Published on March 21, 2022 in Treatment

What are the latest updates in the Phase 3 study of gilteritinib and AZA vs AZA alone for ND FLT-3 AML in patients ineligible for induction chemotherapy?

Dr. Wang describes the significance of the results on the study of gilteritinib and azacitidine versus azacitidine alone for patients ineligible for induction therapy.

Published on February 28, 2022 in Treatment

What is the current thinking on waiting for genetic information before starting treatment?

In this activity, Dr. Wang explains the importance of waiting for genetic information before starting treatment for this specific subset of patients with AML.

Published on February 23, 2022 in Treatment

What are the treatment options for children with newly diagnosed treatment-related AML?

In this activity, Dr. Kolb discusses the challenge regarding available treatment options for children with newly diagnosed treatment-related AML.

Published on January 24, 2022 in Treatment

What are the most widely recognized treatment-related risk factors for secondary AML in children?

Join Dr. Kolb as he discusses treatment-related risk factors for secondary AML in children.

Published on January 10, 2022 in Treatment

What puts children at risk for secondary AML?

In this activity, pediatric oncologist Andy Kolb explains the risk for secondary AML in children.

Published on December 22, 2021 in Treatment

When considering venetoclax plus azacitidine or decitabine, does a patient’s mutational status matter?

If you are considering venetoclax plus azacitidine or decitabine as a treatment option for your patient, hear what Dr. Jonas has to say regarding a mutational status.

Published on December 15, 2021 in Treatment

Venetoclax plus azacytidine, venetoclax plus decitabine or venetoclax plus low-dose cytarabine; how do you determine which combination therapy to use on your patients with AML?

There are three FDA-approved combinations for patients with AML. In this activity, Dr. Jonas discusses how to determine which combination therapy is the most appropriate for specific patients.

Published on December 1, 2021 in Treatment

Where does the combination of venetoclax with decitabine or azacitidine or LDAC fit in the treatment paradigm for AML?

In this activity, Dr. Jonas discusses combination therapies for patients with AML and where they fit in the treatment paradigm.

Published on November 22, 2021 in Treatment

What is the best approach to the therapy of patients with P53-mutated AML?

Dr. Amir Fathi provides his approach to best therapy of patients with P53-mutated AML.

Published on November 10, 2021 in Treatment